Recarbrio(relebactam)
Recarbrio (relebactam) is a small molecule pharmaceutical. Relebactam was first approved as Recarbrio on 2019-07-16. It is used to treat intraabdominal infections, pyelonephritis, and urinary tract infections in the USA. It has been approved in Europe to treat gram-negative bacterial infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Recarbrio
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cilastatin sodium
+
Imipenem
+
Relebactam
Tradename
Company
Number
Date
Products
RECARBRIOMerck & CoN-212819 RX2019-07-16
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
recarbrioNew Drug Application2024-10-28
Agency Specific
FDA
EMA
Expiration
Code
CILASTATIN SODIUM / IMIPENEM / RELEBACTAM, RECARBRIO, MSD MERCK CO
2029-07-16GAIN
2024-07-16NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Cilastatin Sodium / Imipenem / Relebactam, Recarbrio, Msd Merck Co
84870932029-11-19DS, DPU-2586, U-2587, U-2840
ATC Codes
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01D: Other beta-lactam antibacterials in atc
J01DH: Carbapenems
J01DH56: Imipenem, cilastatin and relebactam
HCPCS
Code
Description
J0742
Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
Clinical
No data
Drug
General
Drug common nameRelebactam
INNrelebactam
Description
Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio).
...
More
Classification
Small molecule
Drug classbeta-lactamase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O.O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
Identifiers
PDB
CAS-ID1174018-99-5
RxCUI
ChEMBL IDCHEMBL3301605
ChEBI ID
PubChem CID44129647
DrugBankDB12377
UNII ID1OQF7TT3PF (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use